Factor IX Inhibitors in Hemophilia B

Textbook of Hemophilia: Second Edition

Volumn , Issue , 2010, Pages 94-96

  Lusher, Jeanne M ^a,b   Chitlur, Meera ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Bleeding episode management in patients with factor IX inhibitors; Factor (F) IX inhibitors, uncommon in 3 of persons with hemophilia B; Factor IX inhibitors in hemophilia B; FEIBA VH, effective in bleeding situations; Hemophilia patient B management complications by factor IX inhibitor; Immune tolerance induction (ITI) regimen; Mutations in FIX gene increased incidence of inhibitor development; Patients with inhibitor to FIX and anaphylaxis history to FIX treatment with rFVIIa; Scientific and Standardization Committee (SSC)

Indexed keywords

EID: 84885766604     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318555.ch14     Document Type: Chapter

References (23)

1. Lusher J. Natural history of inhibitors in severe hemophilia A and B: incidence and prevalence. In: Rodriguez-Merchan EC, Lee CA (eds.) Inhibitors in Patients with Haemophilia. Oxford: Blackwell Science Ltd., 2002: 3-8.
2. Lusher JM. Inhibitors in young boys with haemophilia. Baillieres ' Clin Haematol 2000; 3: 457-68.
3. Bicococchi M, Pasino M, Rosano C, et al. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia 2006; 12: 263-270.
4. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX defi ciency a report of the ISTC-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-31.
5. High HA. Factor IX molecular structure, epitopes and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, et al. (eds.) New York: Plenum Press, 1995: 79-86.
6. Thorland ED, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-5.
7. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the infl uence of non-genetic risk factors. Haemophilia 2006; 12 ( Suppl. 6 ): 8-14.
8. Astermark J. Why do inhibitors develop? Principles of and factors infl uencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 ( Suppl. 3 ): 52-60.
9. Warrier I. ITI in hemophilia B: Possibilities and problems. The International Monitor on Hemophilia. 10 Year Anniversary Issue, 2003: 20-23.
10. Warrier I, Ewenstein B, Koerper M, et al. FIX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
11. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. In: Varon D, Martinowitz U, Heim M (eds.) Haemophilia and Related Disorders. Haemophilia, volume 4. Oxford: Blackwell Science Ltd., 1998: 574-6.
12. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-16.
13. Dharnidharka VR, Takemoto C, Ewenstein BM, et al. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol 1998; 12: 654-7.
14. Warrier I. Factor IX inhibitors and anaphylaxis. In: Rodriguez-Merchan ED, Lee CA (eds.) Inhibitors in Patients with Haemophilia. Oxford: Blackwell Science Ltd., 2002: 87-91.
15. Astermark J, Rocino A, von Depka A M, et al. Current use of bypassing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
16. Sumner MJ, Geldziler G, Pedersen M, et al. Treatment of acquired haemophilia with recombinant activated FVIIa: A critical appraisal. Haemophilia 2007; 13: 451-61.
17. Hedner U. Products used to treat hemophilia: Recombinant factor VIIa. In: Lee CA, Berntorp EE, Hoots WK (eds.) Textbook of Hemophilia, Vol. 2. Oxford: Blackwell Publishing, 2007: 147-152.
18. Brown SA. Treatment of inhibitors in hemophilia B. In: Lee CA, Berntorp EE, Hoots WK (eds.) Textbook of Hemophilia, Vol. 1. Oxford: Blackwell Publishing, 2007: 101-5.
19. Lacy L. Economic impact of treating inhibitor patients. Pathophysiol Haemost Thromb 2002; 32 ( Suppl. 1 ): 29-32.
20. Kenet G, Lubetsky A, Luboshitz J, et al. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Hemost 2003; 1: 450-5.
21. Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and effi cacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
22. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-22.
23. Lusher JM. Rituximab and desensitization for a patient with factor IX defi ciency (review). The International Monitor on Hemophilia 2008; 2: 38-40.